Transforming the prevention of viral respiratory tract diseases
Pneumagen is focused on finding innovative solutions designed to prevent viral infections. We aim to do this by offering patients protection against a range of respiratory viruses, such as Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), Human Rhino Virus (hRV) and Coronaviruses (CoV) including SARS-CoV-2.
Pneumagen is developing Neumifil, a novel intranasal spray designed to provide at-risk patients with an easy to use, broad-spectrum antiviral treatment to reduce, and prevent respiratory disease exacerbations caused by viral infections.
Neumifil was generated using Pneumagen’s proprietary GycoTarge™ platform.
Broad therapeutic application across a range of respiratory viruses
Pneumagen is harnessing its platform technology, GlycoTarge™ to develop glycan targeted Carbohydrate Binding Module domains (mCBMs) derived from bacterial glycosidases for the prevention of a broad range of respiratory viruses including Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), Human Rhino Virus (hRV) and Coronaviruses.
Pneumagen has engineered oligomers of monomeric sialic acid binding mCBMs (mCBM40s) by genetically linking copies in tandem, with a trimerisation domain, resulting in multivalent proteins (mCBM40s) with a greatly increased binding affinity for sialic acid.
Pneumagen has active research programmes to explore the use of mCBMs against other viral pathogens, including those that cause infections in humans.